China Sky One Medical, Inc. Announces Health Food Product Pipeline

Harbin, China, Jan. 11, 2011 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. (“China Sky One Medical” or “the Company”) (Nasdaq: CSKI), a leading fully integrated pharmaceutical company in the People’s Republic of China (“PRC”), today announced that following the Tang Wang He forest land acquisition, the Company plans to develop, manufacture and market thirteen new health food products, including teas, oral liquids and herbal wines. These products are expected to receive approvals from China‘s State Food and Drug Administration (“SFDA”) in 2011. The Company will leverage its existing sales network to sell the following new products to consumers through pharmacies:

The Company also reached an agreement with the research division of Heilongjiang Traditional Chinese Medicine University, which will transfer the ownership of eleven patch products at fair market value prices to the Company upon receipt of corresponding production approvals. These products include: Breast and Uterus Patch, Heart Patch, Headache Patch, Intestines Patch, Bowel Relaxing Patch, Onychomycosis Patch, Dry Skin Patch, Cold and Fever Patch, Carsickness Patch, Bone Healing Patch, and Waist Patch.

“We look forward to the commercial launch of these new health food and patch products and expect to continue to diversify our rich product portfolio to strengthen the Company’s competitive position and support sustainable long-term growth,” said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. “We are now working on the sales forecast for these new products and will update investors with the 2011 full year financial forecast soon.”

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio-Engineering Company Limited, Heilongjiang Tianlong Pharmaceutical, Inc. and Peng Lai Jin Chuang Pharmaceutical Company, the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn.

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe,”“expect,”“may,”“will,”“should,”“project,”“plan,”“seek,”“intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the Company’s development of product pipeline. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

SOURCE China Sky One Medical, Inc.